Table 2.
Clinicopathological characteristics and comparison between the UTUC recurrence group and the non-UTUC recurrence group.
| Variables | UTUC recurrence group | Non-UTUC recurrence group | P value |
|---|---|---|---|
| n (%) | n (%) | ||
| N | 19 (2.2%) | 845 (97.8%) | |
| Period of follow-up from initial TURBT, mean ± SD | 58.1 ± 46.8 | 74.7 ± 70.6 | 0.31 |
| Age at initial TURBT, years, mean ± SD | 71.6 ± 5.9 | 76.5 ± 11.9 | 0.078 |
| Sex | |||
| Male | 16 (84.2%) | 727 (86.0%) | |
| Female | 3 (15.8%) | 118 (14.0%) | |
| ECOG-PS | 1 | ||
| 0-1 | 19 (100.0%) | 828 (98.0%) | |
| ≥2 | 0 (0.0%) | 17 (2.0%) | |
| Smoking history | 1.00 | ||
| Never | 14 (73.7%) | 611 (72.3%) | |
| Former/Current | 5 (26.3%) | 227 (26.9%) | |
| Unknown | 0 (0.0%) | 7 (0.8%) | |
| Tumor size | 0.026 | ||
| <30 mm | 10 (52.6%) | 646 (76.4%) | |
| ≥30 mm | 9 (47.4%) | 199 (23.6%) | |
| Multiplicity | 0.64 | ||
| Single | 12 (63.2%) | 474 (56.1%) | |
| Multiple | 7 (36.8%) | 371 (43.9%) | |
| Clinical T category | <0.001 | ||
| Ta | 0 (0.0%) | 413 (48.9%) | |
| Tis | 4 (21.1%) | 35 (4.1%) | |
| T1 | 15 (78.9%) | 397 (47.0%) | |
| Grade (WHO 1973) | <0.001 | ||
| Grade 1 | 1 (5.3%) | 164 (19.4%) | |
| Grade 2 | 2 (10.5%) | 406 (48.0%) | |
| Grade 3 | 16 (84.2%) | 275 (32.5%) | |
| Grade (WHO 2004) | 0.001 | ||
| Low grade | 3 (15.8%) | 463 (54.8%) | |
| High grade | 16 (84.2%) | 382 (45.2%) | |
| CIS | <0.001 | ||
| Negative | 6 (31.6%) | 663 (78.5%) | |
| Positive | 13 (68.4%) | 182 (21.5%) | |
| Prostate-involving CIS | 0.44 | ||
| Negative | 18 (94.7%) | 820 (97.0%) | |
| Positive | 1 (5.3%) | 25 (3.0%) | |
| LVI | 0.058 | ||
| Negative | 14 (73.7%) | 750 (88.8%) | |
| Positive | 5 (26.3%) | 95 (11.2%) | |
| Variant histology | 0.46 | ||
| Negative | 18 (94.7%) | 819 (96.9%) | |
| Positive | 1 (5.3%) | 26 (3.1%) | |
| Intravesical therapy after TURBT | <0.001 | ||
| None | 3 (15.8%) | 473 (56.0%) | |
| BCG | 16 (84.2%) | 239 (28.3%) | |
| IPIC | 0 (0.0%) | 116 (13.7%) | |
| BCG + IPIC | 0 (0.0%) | 17 (2.0%) | |
| Risk classification† | <0.001 | ||
| Low | 0 (0.0%) | 186 (22.0%) | |
| Intermidiate | 0 (0.0%) | 182 (21.5%) | |
| High | 8 (42.1%) | 220 (26.0%) | |
| Highest | 11 (57.9%) | 257 (30.4%) |
BCG: Bacillus Calmette-Guérin; CIS: carcinoma in situ; ECOG-PS: Eastern Cooperative Oncology Group performance status; IPIC: immediate postoperative instillation of chemotherapy; LVI: lymphovascular invasion; SD: standard deviation; TURBT: transurethral resection of bladder tumor; UTUC: upper urinary tract urothelial carcinoma; WHO: World Health Organization. †The risk was classified according to the Clinical Practice Guidelines for Bladder Cancer 2019 [14].